Brief: UroGen Announces FDA Clearance Of IND Application For Immunotherapy UGN-301 Intravesical Solution

UroGen Pharma

29/03/2022 14:18

March 29 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR THE
INVESTIGATIONAL IMMUNOTHERAPY UGN-301 (ZALIFRELIMAB)
INTRAVESICAL SOLUTION IN RECURRENT NON-MUSCLE INVASIVE BLADDER
CANCER
    * UROGEN PHARMA LTD - MULTI-ARM PHASE 1 STUDY IS EXPECTED TO
START
IN APRIL AND SUPPORT DEVELOPMENT OF UGN-301 IN HIGH-GRADE (HG)
NMIBC

Source text for Eikon:  ID:nBw4lBgTya 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))